FDA panel backs boosters for elderly, high-risk
Dealing the White House a stinging setback, an FDA panel overwhelmingly rejected a plan to give Pfizer COVID-19 booster shots across the board, instead endorsing the extra dose for those who are 65 or older or run a high risk of severe disease. (Sept. 17)
